Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Streptavidin (SA)-biotin pretargeted radioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy in model systems, but SA immunogenicity and interference by endogenous biotin may complicate clinical translation of this approach. In this study, we engineered...

Full description

Bibliographic Details
Main Authors: Green, Damian J., Frayo, Shani L., Lin, Yukang, Hamlin, Donald K., Fisher, Darrell R., Frost, Sofia H.L., Kenoyer, Aimee L., Hylarides, Mark D., Gopal, Ajay K., Gooley, Theodore A., Orozco, Johnnie J., Till, Brian G., O'Steen, Shyril, Orcutt, Kelly Davis, Wilbur, D. Scott, Wittrup, Karl Dane, Press, Oliver W.
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering
Format: Article
Language:English
Published: American Association for Cancer Research (AACR) 2020
Online Access:https://hdl.handle.net/1721.1/125642

Internet

https://hdl.handle.net/1721.1/125642

Similar Items